炎症・再生
Online ISSN : 1880-5795
Print ISSN : 1346-8022
ISSN-L : 1346-8022
Zaltoprofenの炎症部位選択的プロスタグランジン生成抑制作用
國上 敏浩内田 あおい西岡 浩一郎平手 謙二齋藤 輝信
著者情報
ジャーナル フリー

2001 年 21 巻 3 号 p. 235-241

詳細
抄録
Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the production of primary prostanoids by blocking both cyclooxygenase (COX) -1 and COX-2 activities, and in doing so, not only decrease inflammation and pain, but also promote gastrointestinal tract damage and bleeding.
The inhibitory activities of zaltoprofen (ZP) on the biosynthesis of prostaglandin E2 (PGE2) at the inflammatory site and stomach were compared with those of some NSAIDs (celecoxib : CL, meloxicam : ML, lornoxicam : LR, mofezolac : MF) using the rat carrageenin-air pouch model. At the dose of ZP and CL that inhibited PGE2biosynthesis at the inflammatory site, these hardly inhibited the PGE2release from stomach. In contrast, ML, MF and LR inhibited the biosynthesis of PGE2on both sites at the same dose.
Furthermore these NSAIDs inhibited the carrageenin-induced paw edema, and produced the ulcer in a dose-dependent manner. The safety index, UD50/ED40ratio, of CL, ZP, ML, LR and MF was >103, 11.3, 0.8, 0.8 and 0.1, respectively. These safety indexes correlated well with the tissue selectivity of NSAIDs on PG biosynthesis inhibition.
These results suggest that the PG biosynthesis at the inflammatory site and stomach of the same rat is a very useful parameter for evaluating NSAIDs. It seems that these properties of ZP were contributed to the low ulcerogenic activity on clinical uses.
著者関連情報
© 日本炎症・再生医学会
前の記事 次の記事
feedback
Top